Why Palisade Bio Stock Is Up Today
Why Palisade Bio Stock Is Up Today
Palisade Bio, Inc. (NASDAQ:PALI) shares are trading higher Tuesday after the company entered into a collaboration with Strand Life Sciences.
Palisade Bio, Inc.（纳斯达克股票代码：PALI）周二股价走高，此前该公司与斯特兰德生命科学公司建立了合作关系。
The Details:
细节：
Palisade Bio said its collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative colitis (UC) therapy and provides the company access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.
Palisade Bio表示，其与Strand Life Sciences的合作旨在推进溃疡性结肠炎（UC）治疗的精准医学，并为该公司提供先进的生物信息学工具，这对于了解复杂的疾病途径和预测对PDE4抑制剂的反应至关重要。
"Our partnership with Strand Life Sciences signifies a pivotal advancement in our mission to revolutionize UC treatment," said Dr. Mitch Jones, CMO at Palisade Bio.
Palisade Bio首席营销官米奇·琼斯博士说：“我们与Strand Life Sciences的合作标志着我们在革新UC治疗的使命方面取得了关键进展。”
"By harnessing the power of bioinformatics and leveraging extensive patient datasets, we are highly optimistic in our ability to deliver personalized therapies that offer new hope to patients living with UC. More immediately, the findings from this collaboration will provide valuable guidance and insight for our lead program, PALI-2108."
“通过利用生物信息学的力量并利用广泛的患者数据集，我们对提供个性化疗法的能力高度乐观，这些疗法为UC患者带来新的希望。更直接的是，此次合作的发现将为我们的牵头项目 PALI-2108 提供宝贵的指导和见解。”
Related News: What's Going On With Luxury EV-Maker Lucid's Stock?
相关新闻： 豪华电动汽车制造商Lucid的股票怎么了？
PALI Stock Prediction 2024:
2024 年 PALI 股票预测：
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
股票研究可以成为了解公司基本面的宝贵信息来源。分析师根据公司的基本面和预期的未来收益创建财务模型，以确定股票的目标股价和建议。
Shares of Palisade Bio have an average 1-year price target of $22.50, representing an expected upside of 226.09%.
Palisade Bio的股票1年期平均目标股价为22.50美元，预计上涨幅度为226.09％。
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Palisade Bio, while 1 analysts has a bullish rating.
由于假设的差异，分析师可以得出截然不同的目标价格和建议。没有分析师对Palisade Bio提出看跌建议，而1位分析师的评级看涨。
PALI Price Action: According to Benzinga Pro, Palisade Bio shares are up 27.9% at $6.30 at the time of publication Tuesday.
PALI价格走势：根据Benzinga Pro的数据，在周二发布时，Palisade Bio的股价上涨了27.9％，至6.30美元。
Image: Shutterstock
图片：Shutterstock